Jean-Jacques K.
- Country
- France
- Department
- Hematology
Research Overview
- Evaluation of INCA033989 Efficacy and Safety in Patients with Myelofibrosis or Essential Thrombocythemia within Myeloproliferative Neoplasms
- Phase 1 Evaluation of JNJ-88549968, a T-cell Redirecting Antibody, in Patients with CALR-mutated Myeloproliferative Neoplasms
- Phase 1b Evaluation of CTPS1 Inhibitor STP938 in High-Risk Essential Thrombocythaemia Resistant or Intolerant to Hydroxycarbamide Therapy
Data & Insights
Has run more than one trial at 193 of 353 partner sites.
Specializations
Myelofibrosis Research
The investigator specializes in treating various forms of myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. Their work encompasses treatment approaches for both JAK inhibitor-naïve and JAK inhibitor-resistant cases.
- Advanced therapeutic combinations
- Spleen volume reduction strategies
- Anemia management in myelofibrosis
Polycythemia Vera Studies
The investigator focuses on developing treatments for polycythemia vera, particularly in high-risk patients. Their research includes evaluation of novel therapeutic approaches and comparative studies of different treatment modalities.
- Hematocrit control strategies
- Disease transformation prevention
- JAK2V617F-positive cases
Essential Thrombocythemia Management
The investigator conducts research on essential thrombocythemia, with particular emphasis on treatment-resistant cases and novel therapeutic approaches. Their work includes evaluation of alternative treatments for patients who are intolerant to standard therapies.
- Cytoreductive therapy assessment
- Novel agent evaluation
- Thrombosis prevention strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.